

Beijing, China, 24 January 2025

Ad hoc announcement pursuant to article 53 LR

## Announcement of 2024 Annual Results Forecast

The Board of Lepu Medical Technology (Beijing) Co., Ltd. (the "Company") (SIX: LEPU) hereby announces annual results forecast of 2024.

- It is anticipated that the net profit attributable to shareholders of the listed Company in 2024 will range between RMB 265.00 million and RMB 395.00 million, representing a year on-year decline ranging from 68.61% to 78.94%;
- It is anticipated that the net profit after deducting non recurring gains and losses attributable to shareholders of the listed Company in 2024 will range between RMB 235.00 million and RMB 350.00 million, representing a year-on-year decline ranging from 68.84% to 79.08%;

### 1. Results forecast for the period

(1) Period of the results forecast

From January 1, 2024 to December 31, 2024.

(2) Results forecast

| Items  | This reporting period                                       | Same period last year |
|--|---|-----------------------|
| Net profit attributable to shareholders of the listed company  | RMB 265.00 million ~ 395.00 million                         | RMB 1258.2003 million |
|  | Compared to the same period last year:<br>-68.61% ~ -78.94% |                       |
| Net profit after deducting non recurring gains and losses attributable to shareholders of the listed company | RMB 235.00 million ~ 350.00 million                         | RMB 1123.1163 million |
|  | Compared to the same period last year:<br>-68.84% ~ -79.08% |                       |

## **2. Communication with accounting firms**

The data related to this period's performance forecast is the preliminary calculation result of the company's finance department, which has not been audited by an auditing institution. However, the company has communicated with the auditing agency regarding major issues related to the performance forecast, and there is no significant disagreement between the company and the auditing agency regarding the performance forecast.

## **3. Main reasons for the change in performance**

- (1) During the reporting period, the core business of the company, cardiovascular implant intervention medical device, achieved double-digit growth in revenue. The pharmaceutical sector's FDF business was affected by the clearance of retail channel inventory, resulting in a year-on-year decline in product sale and a significant decrease in revenue, leading to a year-on-year decline in the company's revenue and net profit.
- (2) The company plans to make depreciation of inventory related to emergency products.
- (3) The company plans to make reduction of goodwill.
- (4) Organizational restructuring and optimization of non-strategic business personnel have led to a corresponding increase in operating costs.

## **4. Other related explanations**

- (1) The data in this performance forecast is the preliminary calculation result of the company's finance department and has not been audited by an auditing agency. The specific financial data of the 2024 performance will be disclosed in detail in the company's 2024 annual report. Investors are advised to make cautious decisions and pay attention to investment risks.
- (2) During the reporting period, a series of products, including Vesscrack™ coronary intravascular lithotripsy catheter, RF-Lance® RF puncture generator, MemoSorb® biodegradable atrial septal defect occluder, ScienCrown® transcatheter implantable aortic valve system have been successfully approved for registration by NMPA in China, and the R&D progress of other products has also been smoothly promoted,

laying a foundation for the stable development of the company's cardiovascular implant intervention business in the future.

- (3) During the reporting period, the inventory clearance work of the pharmaceutical retail channel was basically completed, and the pure sales data of the retail channel has significantly improved compared to the previous period, the pharmaceutical sector is expected to grow steadily in 2025.
- (4) During the reporting period, the company has completed its controlling stake in Shanghai Minwei Biotechnology co.,LTD, and the candidate drug MWN105 injection (GLP-1/GIP/FGF21 Fc fusion protein) and MWN109 injection (GLP-1/GIP/GCG fatty acid chain modified peptide) have been approved for clinical trials, MWN101 injection (GLP-1/GIP/GCG Fc fusion protein) is currently in the phase II clinical data compilation stage. The R&D of various innovative drug of the company is steadily advancing according to the plan, which is expected to provide impetus for the transformation of the company's pharmaceutical sector.

## **Contact information**

Lepu Medical

Ms. Weina Jiang

Securities Department

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

## **Disclaimer**

This announcement may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements

are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release. We undertake no obligation, and do not expect to publicly update, or publicly revise, any of the information, forward-looking statements or the conclusions contained herein or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof, whether as a result of new information, future events or otherwise. We accept no liability whatsoever in respect of the achievement of such forward-looking statements and assumptions.